Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer

NCT01453153 is registered in ClinicalTrials.gov with Halozyme Therapeutics as lead sponsor.

NCT NCT01453153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01453153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer
Lead sponsor
Halozyme Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2011
Completion date
May 31, 2015
Enrollment
28 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv pancreatic cancer